Jan 10 (Reuters) - AbbVie said on Tuesday it expects combined peak sales of plaque psoriasis drug Skyrizi and anti-inflammatory medicine Rinvoq to exceed $21 billion in 2027. (Reporting by Leroy Leo in Bengaluru; Editing by Shinjini Ganguli)
Abbvie expects sales of two drugs to exceed $21 bln in 2027
![Reuters logo](/images/reuters.jpg)